Allan C. Golston Sells 2,458 Shares of Stryker Co. (NYSE:SYK) Stock

Stryker Co. (NYSE:SYK) Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the sale, the director now directly owns 14,895 shares of the company’s stock, valued at approximately $5,705,827.65. The trade was a 14.16 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Stryker Price Performance

Shares of SYK stock traded up $2.69 on Wednesday, reaching $388.30. The company had a trading volume of 827,114 shares, compared to its average volume of 1,406,953. The business’s 50-day moving average is $377.69 and its 200 day moving average is $368.08. Stryker Co. has a one year low of $314.93 and a one year high of $406.19. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. The stock has a market capitalization of $148.17 billion, a PE ratio of 50.04, a price-to-earnings-growth ratio of 2.90 and a beta of 0.96.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period in the prior year, the business posted $3.46 earnings per share. Equities research analysts forecast that Stryker Co. will post 13.49 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be given a dividend of $0.84 per share. The ex-dividend date is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a yield of 0.87%. Stryker’s dividend payout ratio is currently 43.30%.

Analysts Set New Price Targets

Several research firms have weighed in on SYK. UBS Group increased their price objective on Stryker from $366.00 to $370.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 30th. StockNews.com lowered shares of Stryker from a “buy” rating to a “hold” rating in a research report on Thursday, January 30th. Royal Bank of Canada boosted their price objective on shares of Stryker from $425.00 to $435.00 and gave the company an “outperform” rating in a report on Wednesday, January 29th. Needham & Company LLC reaffirmed a “buy” rating and set a $442.00 target price on shares of Stryker in a report on Wednesday, January 29th. Finally, Robert W. Baird boosted their price target on Stryker from $378.00 to $405.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. Five research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $420.68.

Hedge Funds Weigh In On Stryker

A number of institutional investors and hedge funds have recently bought and sold shares of SYK. Whittier Trust Co. boosted its position in Stryker by 24.0% during the 3rd quarter. Whittier Trust Co. now owns 4,150 shares of the medical technology company’s stock worth $1,499,000 after buying an additional 804 shares during the period. Foundations Investment Advisors LLC raised its stake in shares of Stryker by 10.0% during the third quarter. Foundations Investment Advisors LLC now owns 1,753 shares of the medical technology company’s stock valued at $633,000 after acquiring an additional 160 shares during the last quarter. Sky Investment Group LLC lifted its holdings in shares of Stryker by 3.7% during the third quarter. Sky Investment Group LLC now owns 15,119 shares of the medical technology company’s stock worth $5,462,000 after purchasing an additional 533 shares during the period. Sequoia Financial Advisors LLC grew its stake in shares of Stryker by 1.7% in the third quarter. Sequoia Financial Advisors LLC now owns 11,236 shares of the medical technology company’s stock worth $4,059,000 after purchasing an additional 187 shares during the last quarter. Finally, Eastern Bank increased its holdings in Stryker by 313.5% in the third quarter. Eastern Bank now owns 3,730 shares of the medical technology company’s stock valued at $1,347,000 after purchasing an additional 2,828 shares during the period. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.